Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML

The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with either KMT2A-rearranged (KMT2A-r) or NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).

Trial Details

NCT ID
NCT07355335
Phase
PHASE1
Sponsor
Massachusetts General Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Ziftomenib
  • Mezigdomide
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Age ≥16 years during dose escalation portion of study, patients must weigh ≥40 kg.
  • Age \>12 years during dose expansion portion of study, patients must weight ≥40 kg.
  • Diagnosis of AML per the WHO Classification of Hematolymphoid Tumors (5th Edition) with documented KMT2A rearrangement or NPM1 cytoplasmic-type (NP…
  • Patients with NPM1 mutated AML must either be FLT3 ITD wild type or have an ITD allelic ratio of \<0.05 (i.e. not eligible for a targeted FLT3 tyro…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →